Trial Profile
A research on imaging of concentration of drug on the skin rash and normal skin tissue in patients with advanced pancreatic cancer treating with gemcitabine and erlotinib.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Dec 2019
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Pharmacokinetics
- 03 Aug 2018 Status changed from active, no longer recruiting to completed.
- 03 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 03 Aug 2015 Planned number of patients changed from 5 to 11 as reported by University Hospital Medical Information Network - Japan.